The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis

Ulusal Travma ve Acil Cerrahi Dergisi

Volumn 15, Issue 2, 2009, Pages 113-119

  Özmen, Füsun ^a,c   Özmen, M Mahir ^b   Özalp, Nejdet ^b   Akar, Nejat ^a  

^a Faculty of Medicine   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c NONE

Author keywords

Arterial thrombosis; Factor V; Gene mutation; MTHFR; Prothrombin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AGAROSE; BLOOD CLOTTING FACTOR 5; DNA; ETHIDIUM BROMIDE; PHENOL; PROTEINASE; PROTHROMBIN; RESTRICTION ENDONUCLEASE;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIGESTION; FEMALE; GENE MUTATION; GENETIC RISK; HEREDITY; HUMAN; MALE; PREVALENCE; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; PREVALENCE; PROTHROMBIN; RISK ASSESSMENT; THROMBOSIS; YOUNG ADULT;

EID: 65249132239     PISSN: 1306696X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
3. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-14.
4. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood 1995;85:1504- 8.
5. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
6. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997;98:353-5.
7. Akar N, Misirlioǧlu M, Akar E, Avcu F, Yalçin A, Sözüöz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 1998;58:249.
8. Gürgey A, Hicsönmez G, Parlak H, Balta G, Celiker A. Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. Am J Hematol 1998;59:179-80.
9. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
10. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
11. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004;127(Pt l):212-9.
12. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
13. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J2003;146:948-57.
14. Mueller T, Marschon R, Dieplinger B, Haidinger D, Gegenhuber A, Poelz W, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg 2005;41:808-15.
15. Samett EJ, Khan AN. Thrombolysis peripheral, www.emedicine.com/Topic861. html 14april 2006.
16. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg506→Gln mutation. Blood Coagul Fibrinolysis 1995;6:245-8.
17. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
19. Foley PW, Irvine CD, Standen GR, Morse C, Smith FT, McGrath C, et al. Activated protein C resistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg 1997 ;5:157-60.
20. Sampram ES, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998;28:624-9.
21. Renner W, Köppel H, Brodmann M, Pabst E, Schallmoser K, Toplak H, et al. Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease. Thromb Haemost 2000;83:20-2.
22. Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest 1999 ;29:1003-9.
23. Rassoul F, Richter V, Janke C, Purschwitz K, Klötzer B, Geisel J, et al. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology 2000;51:189-96.
24. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
25. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994;88:219-22.
26. Gurgey A, Mesci L, Renda Y, Olcay L, Kocak N, Erdem G. Factor V Q 506 mutation in children with thrombosis. Am J Hematol 1996;53:37-9.
27. Gül A, Ozbek U, Oztürk C, Inanç M, Koniçe M, Ozçelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. Br J Rheumatol 1996;35:1178-80.
28. Akar N, Akar E, Dalgin G, Sözüöz A, Omürlü K, Cin S. Frequency of Factor V (1691 G → A) mutation in Turkish population. Thromb Haemost 1997;78:1527-8.
29. Chaida C, Gialeraki A, Tsoukala C, Mandalaki T. Prevalence of the FVQ506 mutation in the Hellenic population. Thromb Haemost 1996;76:127.
30. Gurgey A, Rustemov R, Parlak H, Balta G. Prevalence of factor V Leiden and methylenetetrahydrofolate reductase C677T mutations in Azerbaijan. Thromb Haemost 1998;80:520-l.
31. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med l995;332:912-7.
32. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-34.
33. Siscovick DS, Schwartz SM, Rosendaal FR, Psaty BM. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997;78:7-12.
34. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
35. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996;75:701-2.
36. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995;345:321.
37. Strieker H, Soldati G, Balmelli T, Mombelli G. Homocysteine, vitamins and gene mutations in peripheral arterial disease. Blood Coagul Fibrinolysis 2001; 12:469-75.
38. Ciccarone E, Di Castelnuovo A, Assanelli D, Archetti S, Ruggeri G, Salcuni N, et al. Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients. J Thromb Haemost 2003;l:2540-7.
39. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997;78:990-2.